Geron
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
919 E Hillsdale Blvd Ste 250, Foster Cit...Phone Number
(650) 473-7700Website
www.geron.comRevenue
$204.6 MillionStock Symbol
GERNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Geron
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.Explore more
Geron Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Geron your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Geron
Click to see if Geron had a recent Job posting/layoffs
Check out if Geron is spiking on competitors!
Product Launch: Get notified when Geron launches new products
Geron, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Geron has new funding data
Check if Geron has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Geron recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Geron
Find more new buyers
Compare Similar Companies to Geron
Compare insights from companies similar to Geron, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Geron
$204.6M
201-500
Public
$466M
1990
MR
Michelle RobertsonExecutive Vice President & Chief Financial Officer & Treasurer
Company Profile Activity
Activity Insights
Geron is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Geron is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Geron.
Geron financials insights
Gather financial insights about Geron, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
1996
Stock Offering
$16M
2020
Debt
$75M
2024
Debt
$375M
Geron Tech Stack
A closer look at the technologies used by Geron
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Earnings, Finance, Revenue Operations
Person-Based
Earnings, Finance
Earnings
reported total operating expenses, excluding cost of goods sold, of $60.7 million for Q2 2026 ended June 30, 2026, compared to $60.3 million for the same period in 2025, with continued investments in commercial strategy and CMC partially offset by lower headcount costs from the December 2025 workforce reduction.
Earnings, Spending/Investment, Finance
Earnings
Earnings, Finance
Geron News & Media
Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Geron...Geron to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences:Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective August 17, 2026, it granted stock options to purchase an aggregate of 311,250 shares of common stock to six newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.Geron Corp (GERN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Geron Corp (GERN) reports 17% year-over-year net revenue growth, raises full-year guidance, and progresses regulatory discussions for its IMPACT MF trial.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Geron
Sign Up For FreeTo access detailed company insights
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosi... Read More
